To improve the anti-tumor immune response, DC immunotherapy can be used in conjunction with chemotherapy, radiation therapy, or other targeted therapies such as anti-vascular endothelial growth factor (VEGF) and anti-human epidermal growth factor receptor (HER)-2/neu medications. The gene discussed is VEGFA; the disease is neoplasm.